Muscle ring finger 1 mediates cardiac atrophy in vivo

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 296, Issue 4, 2009, Pages

  Willis, Monte S ^a,b   Rojas, Mauricio ^a   Li, Luge ^b   Selzman, Craig H ^d   Tang, Ru Hang ^b   Stansfield, William E ^b   Rodriguez, Jessica E ^b   Glass, David J ^c   Patterson, Cam ^a,b  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^d UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

Cardiac atrophy; Cardiac hypertrophy; Left ventricular assist device; Ubiquitin ligase

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; DEXAMETHASONE; MUSCLE RING FINGER 1 PROTEIN; MYOSIN HEAVY CHAIN BETA; SMOOTH MUSCLE ACTIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA CONSTRICTION; ARTICLE; ATROPHY; CONTROLLED STUDY; DOPPLER ECHOCARDIOGRAPHY; EXPERIMENTAL MODEL; FEMALE; GENE EXPRESSION; HEART ASSIST DEVICE; HEART DISEASE; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEART MUSCLE ATROPHY; HEART MUSCLE CELL; HEART SIZE; HEART WORK; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; TRANSCRIPTION INITIATION; WILD TYPE;

ACTINS; ANIMALS; ATROPHY; DEXAMETHASONE; DISEASE MODELS, ANIMAL; HEART DISEASES; HEART-ASSIST DEVICES; MICE; MICE, KNOCKOUT; MUSCLE PROTEINS; MYOCARDIUM; MYOCYTES, CARDIAC; NATRIURETIC PEPTIDE, BRAIN; UBIQUITIN-PROTEIN LIGASES; VASOCONSTRICTION; VENTRICULAR MYOSINS;

EID: 66249116681     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00660.2008     Document Type: Article

References (55)

1. Agbenyega ET, Wareham AC. Effect of clenbuterol on skeletal muscle atrophy in mice induced by the glucocorticoid dexamethasone. Comp Biochem Physiol Comp Physiol 102: 141-145, 1992.
2. Arya R, Kedar V, Hwang JR, McDonough H, Li HH, Taylor J, Patterson C. Muscle ring finger protein-1 inhibits PKCe activation and prevents cardiomyocyte hypertrophy. J Cell Biol 167: 1147-1159, 2004.
3. Bodine SC, Latres E, Baumhueter S, Lai VK, Nunez L, Clarke BA, Poueymirou WT, Panaro FJ, Na E, Dharmarajan K, Pan ZQ, Valenzuela DM, DeChiara TM, Stitt TN, Yancopoulos GD, Glass DJ. Identification of ubiquitin ligases required for skeletal muscle atrophy. Science 294: 1704-1708, 2001.
4. Burkhoff D, Klotz S, Mancini DM. LVAD-induced reverse remodeling: basic and clinical implications for myocardial recovery. J Card Fail 12: 227-239, 2006.
5. Centner T, Yano J, Kimura E, McElhinny AS, Pelin K, Witt CC, Bang ML, Trombitas K, Granzier H, Gregorio CC, Sorimachi H, Labeit S. Identification of muscle specific ring finger proteins as potential regulators of the titin kinase domain. J Mol Biol 306: 717-726, 2001.
6. Cipriano C, Gosse P, Bemurat L, Mas D, Lemetayer P, N'Tela G, Clementy J. Prognostic value of left ventricular mass and its evolution during treatment in the Bordeaux cohort of hypertensive patients. Am J Hypertens 14: 524-529, 2001.
7. Clarke BA, Drujan D, Willis MS, Murphy LO, Corpina RA, Burova E, Rakhilin SV, Stitt TN, Patterson C, Latres E, Glass DJ. The E3 ligase MuRF1 degrades myosin heavy chain protein in dexamethasone-treated skeletal muscle. Cell Metab 6: 376-385, 2007.
8. Coleman PS, Parmacek MS, Lesch M, Samarel AM. Protein synthesis and degradation during regression of thyroxine-induced cardiac hypertrophy. J Mol Cell Cardiol 21: 911-925, 1989.
9. Depre C, Wang Q, Yan L, Hedhli N, Peter P, Chen L, Hong C, Hittinger L, Ghaleh B, Sadoshima J, Vatner DE, Vatner SF, Madura K. Activation of the cardiac proteasome during pressure overload promotes ventricular hypertrophy. Circulation 114: 1821-1828, 2006.
10. Devereux RB, Wachtell K, Gerdts E, Boman K, Nieminen MS, Papademetriou V, Rokkedal J, Harris K, Aurup P, Dahlof B. Prognostic significance of left ventricular mass change during treatment of hypertension. JAMA 292: 2350-2356, 2004.
11. Dickhout JG, Austin RC. Proteasomal regulation of cardiac hypertrophy: is demolition necessary for building? Circulation 114: 1796-1798, 2006.
12. Dyadyk AI, Bagriy AE, Lebed IA, Yarovaya NF, Schukina EV, Taradin GG. ACE inhibitors captopril and enalapril induce regression of left ventricular hypertrophy in hypertensive patients with chronic renal failure. Nephrol Dial Transplant 12: 945-951, 1997.
13. Fielitz J, Kim MS, Shelton JM, Latif S, Spencer JA, Glass DJ, Richardson JA, Bassel-Duby R, Olson EN. Myosin accumulation and striated muscle myopathy result from the loss of muscle RING finger 1 and 3. J Clin Invest 117: 2486-2495, 2007.
14. Frey N, Katus HA, Olson EN, Hill JA. Hypertrophy of the heart: a new therapeutic target? Circulation 109: 1580-1589, 2004.
15. Frey N, Olson EN. Cardiac hypertrophy: the good, the bad, and the ugly. Annu Rev Physiol 65: 45-79, 2003.
16. Gilson H, Schakman O, Combaret L, Lause P, Grobet L, Attaix D, Ketelslegers JM, Thissen JP. Myostatin gene deletion prevents glucocorticoid-induced muscle atrophy. Endocrinology 148: 452-460, 2007.
17. Goldberg AL. Protein degradation and protection against misfolded or damaged proteins. Nature 426: 895-899, 2003.
18. Haider AW, Larson MG, Benjamin EJ, Levy D. Increased left ventricular mass and hypertrophy are associated with increased risk for sudden death. J Am Coll Cardiol 32: 1454-1459, 1998.
19. Hill JA, Karimi M, Kutschke W, Davisson RL, Zimmerman K, Wang Z, Kerber RE, Weiss RM. Cardiac hypertrophy is not a required compensatory response to short-term pressure overload. Circulation 101: 2863-2869, 2000.
20. Hill JA, Olson EN. Cardiac plasticity. N Engl J Med 358: 1370-1380, 2008.
21. Hoshijima M. Mechanical stress-strain sensors embedded in cardiac cytoskeleton: Z disk, titin, and associated structures. Am J Physiol Heart Circ Physiol 290: H1313-H1325, 2006.
22. Ikonomidis I, Tsoukas A, Parthenakis F, Gournizakis A, Kassimatis A, Rallidis L, Nihoyannopoulos P. Four year follow up of aortic valve replacement for isolated aortic stenosis: a link between reduction in pressure overload, regression of left ventricular hypertrophy, and diastolic function. Heart 86: 309-316, 2001.
23. Israel BA, Sherman FS, Guthrie RD. Hypertrophic cardiomyopathy associated with dexamethasone therapy for chronic lung disease in preterm infants. Am J Perinatol 10: 307-310, 1993.
24. Kedar V, McDonough H, Arya R, Li HH, Rockman HA, Patterson C. Muscle-specific RING finger 1 is a bona fide ubiquitin ligase that degrades cardiac troponin I. Proc Natl Acad Sci USA 101: 18135-18140, 2004.
25. Koren MJ, Devereux RB, Casale PN, Savage DD, Laragh JH. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med 114: 345-352, 1991.
26. Koren MJ, Ulin RJ, Koren AT, Laragh JH, Devereux RB. Left ventricular mass change during treatment and outcome in patients with essential hypertension. Am J Hypertens 15: 1021-1028, 2002.
27. Koyama S, Hata S, Witt CC, Ono Y, Lerche S, Ojima K, Chiba T, Doi N, Kitamura F, Tanaka K, Abe K, Witt SH, Rybin V, Gasch A, Franz T, Labeit S, Sorimachi H. Muscle RING-finger protein-1 (MuRF1) as a connector of muscle energy metabolism and protein synthesis. J Mol Biol 376: 1224-1236, 2008.
28. Krumholz HM, Larson M, Levy D. Prognosis of left ventricular geometric patterns in the Framingham Heart Study. J Am Coll Cardiol 25: 879-884, 1995.
29. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 322: 1561-1566, 1990.
30. Loureiro J, Smith S, Fonfara S, Swift S, James R, Dukes-McEwan J. Canine dynamic left ventricular outflow tract obstruction: assessment of myocardial function and clinical outcome. J Small Anim Pract 49: 578 -586, 2008.
31. Maybaum S, Mancini D, Xydas S, Starling RC, Aaronson K, Pagani FD, Miller LW, Margulies K, McRee S, Frazier OH, Torre-Amione G. Cardiac improvement during mechanical circulatory support: a prospective multicenter study of the LVAD Working Group. Circulation 115: 2497-2505, 2007.
32. McElhinny AS, Kakinuma K, Sorimachi H, Labeit S, Gregorio CC. Muscle-specific RING finger-1 interacts with titin to regulate sarcomeric M-line and thick filament structure and may have nuclear functions via its interaction with glucocorticoid modulatory element binding protein-1. J Cell Biol 157: 125-136, 2002.
33. Morgan HE, Kira Y, Gordon EE. Aortic pressure, substrate utilization and protein synthesis. Eur Heart J 5, Suppl F: 141-146, 1984.
34. Mrosek M, Labeit D, Witt S, Heerklotz H, von Castelmur E, Labeit S, Mayans O. Molecular determinants for the recruitment of the ubiquitinligase MuRF-1 onto M-line titin. FASEB J 21: 1383-1392, 2007.
35. Muiesan ML, Salvetti M, Rizzoni D, Castellano M, Donato F, Agabiti-Rosei E. Association of change in left ventricular mass with prognosis during long-term antihypertensive treatment. J Hypertens 13: 1091-1095, 1995.
36. Okin PM, Devereux RB, Jern S, Kjeldsen SE, Julius S, Nieminen MS, Snapinn S, Harris KE, Aurup P, Edelman JM, Wedel H, Lindholm LH, Dahlof B. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. JAMA 292: 2343-2349, 2004.
37. Parmacek MS, Magid NM, Lesch M, Decker RS, Samarel AM. Cardiac protein synthesis and degradation during thyroxine-induced left ventricular hypertrophy. Am J Physiol Cell Physiol 251: C727-C736, 1986.
38. Riede FT, Schulze E, Vogt L, Schramm D. Irreversible cardiac changes after dexamethasone treatment for bronchopulmonary dysplasia. Pediatr Cardiol 22: 363-364, 2001.
39. Schillaci G. Pharmacogenomics of left ventricular hypertrophy reversal: beyond the "one size fits all" approach to antihypertensive therapy. J Hypertens 22: 2273-2275, 2004.
40. Selzman CH, Sheridan BC. Off-pump insertion of continuous flow left ventricular assist devices. J Card Surg 22: 320-322, 2007.
41. Skelton R, Gill AB, Parsons JM. Cardiac effects of short course dexa-methasone in preterm infants. Arch Dis Child Fetal Neonatal Ed 78: F133-F137, 1998.
42. Stansfield WE, Rojas M, Corn D, Willis M, Patterson C, Smyth SS, Selzman CH. Characterization of a model to independently study regression of ventricular hypertrophy. J Surg Res 142: 387-393, 2007.
43. Ueberham E, Low R, Ueberham U, Schonig K, Bujard H, Gebhardt R. Conditional tetracycline-regulated expression of TGF-beta1 in liver of transgenic mice leads to reversible intermediary fibrosis. Hepatology 37: 1067-1078, 2003.
44. Verdecchia P, Angeli F, Borgioni C, Gattobigio R, de Simone G, Devereux RB, Porcellati C. Changes in cardiovascular risk by reduction of left ventricular mass in hypertension: a meta-analysis. Am J Hypertens 16: 895-899, 2003.
45. Verdecchia P, Schillaci G, Borgioni C, Ciucci A, Gattobigio R, Zampi, Reboldi G, Porcellati C. Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circulation 97: 48 -54, 1998.
46. Villari B, Vassalli G, Monrad ES, Chiariello M, Turina M, Hess OM. Normalization of diastolic dysfunction in aortic stenosis late after valve replacement. Circulation 91: 2353-2358, 1995.
47. Walther T, Schubert A, Falk V, Binner C, Kanev A, Bleiziffer S, Walther C, Doll N, Autschbach R, Mohr FW. Regression of left ventricular hypertrophy after surgical therapy for aortic stenosis is associated with changes in extracellular matrix gene expression. Circulation 104: I54-58, 2001.
48. Werner JC, Sicard RE, Hansen TW, Solomon E, Cowett RM, Oh W. Hypertrophic cardiomyopathy associated with dexamethasone therapy for bronchopulmonary dysplasia. J Pediatr 120: 286-291, 1992.
49. Willis MS, Ike C, Li L, Wang DZ, Glass DJ, Patterson C. Muscle ring finger 1, but not muscle ring finger 2, regulates cardiac hypertrophy in vivo. Circ Res 100: 456-459, 2007.
50. Willis MS, Schisler JC, Patterson C. Appetite for destruction: E3 ubiquitin-ligase protection in cardiac disease. Future Cardiol 4: 65-75, 2008.
51. Witt SH, Granzier H, Witt CC, Labeit S. MURF-1 and MURF-2 target a specific subset of myofibrillar proteins redundantly: towards understanding MURF-dependent muscle ubiquitination. J Mol Biol 350: 713-722, 2005.
52. Yeh TF, Lin YJ, Hsieh WS, Lin HC, Lin CH, Chen JY, Kao HA, Chien CH. Early postnatal dexamethasone therapy for the prevention of chronic lung disease in preterm infants with respiratory distress syndrome: a multicenter clinical trial. Pediatrics 100: E3, 1997.
53. Zafeiridis A, Jeevanandam V, Houser SR, Margulies KB. Regression of cellular hypertrophy after left ventricular assist device support. Circulation 98: 656-662, 1998.
54. Zecca E, Papacci P, Maggio L, Gallini F, Elia S, De Rosa G, Romagnoli C. Cardiac adverse effects of early dexamethasone treatment in preterm infants: a randomized clinical trial. J Clin Pharmacol 41: 1075-1081, 2001.
55. Zhao TJ, Yan YB, Liu Y, Zhou HM. The generation of the oxidized form of creatine kinase is a negative regulation on muscle creatine kinase. J Biol Chem 282: 12022-12029, 2007.